| Document |
Document Title |
|
WO/2024/084517A1 |
This invention provides a group of novel L-amino acid esters substituted 3-phenyl- 3-(aryloxy)propan-1-amine derivatives of the following structural Formula I, wherein, the groups R1, R2 and R3 are defined in the specification having ant...
|
|
WO/2024/078413A1 |
Disclosed in the present invention are an acryloyl formate compound for LED photopolymerization, and a preparation method therefor and a use thereof. The acryloyl formate compound can be used as an initiator for LED photopolymerization. ...
|
|
WO/2024/046955A1 |
The present invention relates to a process for preparing p-aminobenzoic acid-2-ethylhexyl ester comprising reacting p-nitrobenzoic acid-2-ethylhexyl ester with hydrogen in the presence of a catalyst, wherein the reaction is performed in ...
|
|
WO/2024/046786A1 |
The present invention deals with a process for preparing a solid, storage stable composition comprising at least one aminocarboxylate complexing agent.
|
|
WO/2024/044147A1 |
Provided herein are methods for purifying an ionizable amino lipid (IAL) composition comprising impurities that may react with polynucleotides, such as mRNA. Methods for purifying IAL compositions comprise one or more scavenging-removal ...
|
|
WO/2024/032613A1 |
Provided is a drug delivery system suitable for tumor administration, which particularly relates to a lipid composition suitable for intratumoral administration. A therapeutic agent and/or a preventive the lipid composition comprises is ...
|
|
WO/2024/034666A1 |
A ruthenium complex according to one aspect of the present disclosure is represented by general formula (1). In general formula (1), R1 represents a hydrogen atom, a phenyl group, or a monovalent substituent which is obtained by substitu...
|
|
WO/2024/010840A1 |
Methods and compositions including (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxyl
ic acid or a pharmaceutically acceptable salt thereof are provided for use in treating cancer and inhibiting cancer proliferation and metasta...
|
|
WO/2024/003032A1 |
The invention relates to a method for obtaining an aminobenzoic acid or an aliphatic saturated C4- 6-dicarboxylic acid from an aqueous solution, comprising: A) producing the organic acid, wherein a) the organic acid is crystallised from ...
|
|
WO/2024/000920A1 |
Disclosed in the present invention is a method for preparing a β-trifluoromethylenamine compound on the basis of organic dye catalysis. The present invention belongs to the technical fields of the synthesis of medicines, pesticide produ...
|
|
WO/2024/003942A1 |
The present invention relates to an improved process for the preparation of 5 Selumetinib sulfate of Formula-(I).
|
|
WO/2024/003915A1 |
A crystalline form of indaziflam, processes for the preparation thereof, an agrochemical composition containing the crystalline form of indaziflam and a process for the preparation of the agrochemical composition.
|
|
WO/2024/006701A1 |
A method for preparing dialkyl amino acid ester sulfonates having reduced levels of byproducts, particularly sulfonic acid ester and dialkyl ether, is disclosed. The method involves reacting an amino acid having at least two carboxylic a...
|
|
WO/2023/241577A1 |
The present application relates to the field of drug carriers, and specifically discloses a cationic lipid compound, and a preparation method therefor and a use thereof. The cationic lipid compound comprises a compound represented by for...
|
|
WO/2023/242181A1 |
The invention discloses a method for obtaining crystalline diethylamino hydroxybenzoyl hexyl benzoate (I) comprising steps (a) to (d), (a) providing a feed comprising diethylamino hydroxybenzoyl hexyl benzoate (I) and at least a first cr...
|
|
WO/2023/236953A1 |
Disclosed are a nitrogen-containing chain compound, a preparation method, a composition containing said compound, and a use thereof. Provided is a nitrogen-containing chain compound represented by formula (I) or a pharmaceutically accept...
|
|
WO/2023/232148A1 |
Provided in the present invention is a new amino acid-based cationic lipid containing unsaturated bonds, the structure of which is as shown in general formula (1), and the definitions of each symbol in the formula is consistent with thos...
|
|
WO/2023/234425A1 |
The present invention provides a novel active ester of an amino acid to be used for amino acylation of tRNA, said ester being capable of reducing risks to safety and waste. The present invention provides a compound represented by formula...
|
|
WO/2023/202652A9 |
Provided herein is a pharmaceutical combination comprising a Glutamine antagonist, or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof, and an isotopic substitution thereof, and an additional therape...
|
|
WO/2023/229997A1 |
According to various aspects of this disclosure, the present disclosure relates to an automated process for the radiosynthesis of [18F]FSPG, a positron emission tracer. The automated optimized process of the present invention enables the...
|
|
WO/2023/226263A1 |
The present invention relates to the technical field of organic synthesis, in particular to an anilinoacetate and a synthesis method therefor. The synthesis method for an anilinoacetate comprises: S1, adding an anilinoacetate solution an...
|
|
WO/2023/222081A1 |
Provided are a long-chain alkyl ester amine lipid compound represented by formula I, a preparation method therefor, and a use thereof in nucleic acid delivery. The long-chain alkyl ester amine lipid compound, as a lipid molecule, has exc...
|
|
WO/2023/224418A1 |
The present invention relates to a method for producing, from fatty alcohols, various monomers that are used in the production of synthetic resins.
|
|
WO/2023/219152A1 |
One aspect of the present invention relates to a method for producing a salt of an amino acid, a salt of a peptide compound, or a solvate of either one of the salts, the method comprising the following steps (A) and (B). Step (A): a st...
|
|
WO/2023/219156A1 |
One aspect of the present invention pertains to a method for producing an amino acid, the method comprising a step for conducting a reaction of (i) or (ii), in the presence of a compound D represented by formula (1), a reducing agent, an...
|
|
WO/2023/211956A1 |
Esterquat fabric softening compositions are disclosed that comprise an esterquat fabric softening active derived from biorenewable sources and having a Biorenewable Carbon Index (BCI) of 100. The esterquat fabric softening active is the ...
|
|
WO/2023/202651A1 |
Provided herein are new polymorph forms of the compound of Formula (I), pharmaceutical composition thereof, and methods of preparing them and using them.
|
|
WO/2023/203897A1 |
The present invention provides a diamine represented by formula (1); a method for producing the same; and a polyamic acid and polyimide produced from this diamine.
|
|
WO/2023/187044A1 |
A process for the production of a surfactant of formula (I) is provided, as well as a surfactant composition. Moreover, specific surfactants and compositions thereof are provided, as well as their use in a wide variety of applications su...
|
|
WO/2023/187697A1 |
The present invention relates to a process for the preparation of belumosudil mesylate and its crystalline form. Further, the present invention relates to a 10 pharmaceutical composition comprising a therapeutically effective amount of t...
|
|
WO/2023/187602A1 |
The present invention relates to the process for obtaining disodium tyrosine, preferably dihydrate, in a crystalline form, by spray drying technology.
|
|
WO/2023/187049A1 |
The present invention relates to a process for separating at least one ε-caprolactam oligomeric compound CPO from a stream SR comprising said at least one CPO and ε-caprolactam monomeric compound CPM.
|
|
WO/2023/179462A1 |
Disclosed in the present invention are a cationic lipid compound, a preparation method therefor and the use thereof, and an mRNA delivery system, which solve the problem of there being an urgent need to develop cationic lipids with high ...
|
|
WO/2023/181053A1 |
The present invention relates to an improved process for purification of Robenacoxib. More particularly, the present invention relates to a process for obtaining crystalline Robenacoxib in high yield with high purity. Furthermore, the pr...
|
|
WO/2023/180219A1 |
A method for synthesis of halide salts of the general formula: Zn+X- n; the method comprising reacting a first reactant being formate salt with a second reactant being a diatom halogen: X2.
|
|
WO/2023/144678A1 |
The object of the present invention is a process for the purification of 5-ASA. This process allows to obtain a product having a lower content of impurities and in an increased yield.
|
|
WO/2023/142600A1 |
The present invention relates to an ionizable amino lipid represented by formula (I) or a pharmaceutically acceptable salt thereof. The amino lipid can be used to deliver nucleic acids and small molecule drugs and has two ester bonds, wh...
|
|
WO/2023/131645A1 |
The invention provides an improved method for preparing lysine acetylsalicylate · glycine (LASAG) that allows for high yields without the need for an addition of seed crystal, as well as yielding controlled, small particle sizes (median...
|
|
WO/2023/126469A1 |
The current invention relates to cell - cell interaction and in particular to cellular avidity. Provided are improved means and methods to study cell - cell interaction and characterizing cellular avidity. When target cells were prepared...
|
|
WO/2023/126006A1 |
Disclosed are a novel cationic lipid and a PEGylated derivative thereof, and a cationic liposome, cationic liposome nucleic acid pharmaceutical composition, and cationic liposome nucleic acid pharmaceutical composition preparation contai...
|
|
WO/2023/127752A1 |
A polypeptide that has a sequence having a sequence identity of 90% or more with respect to a sequence obtained by modifying one amino acid residue in the amino acid sequence represented by SEQ ID NO: 1, and that has a catalytic activity...
|
|
WO/2023/127869A1 |
The present invention pertains to a method for producing a N-monoalkyl amino acid or an ester thereof, or a peptide including the N-monoalkyl amino acid or an ester thereof, the method comprising an alkylating step for mixing, in the pre...
|
|
WO/2023/115691A1 |
Provided are a pleuromutilin derivative with an amino side chain, and a preparation method therefor and the use thereof. The pleuromutilin derivative is a compound having a structure as shown in formula 2 or a pharmaceutically acceptable...
|
|
WO/2023/117756A1 |
The present invention relates to a process for recovering aminobenzoic acid from an aqueous mother liquor which is produced on crystallization of aminobenzoic acid. The process comprises a step (A) of fermenting a suitable fermentable ra...
|
|
WO/2023/112939A1 |
A method for purifying a composition that comprises a step for dissolving the composition containing a compound represented by formula(1) [in formula (1): R1 represents -N(R2)-R2 (wherein R2 represents a C1-C4 alkyl group); R3 and R4 rep...
|
|
WO/2023/109157A1 |
Provided in the present invention are procaine penicillin and a preparation method therefor, and an impurity and an impurity control method, wherein the content of RRT0.24 impurity in the procaine penicillin is less than 0.13%. The prepa...
|
|
WO/2023/106413A1 |
The present invention provides a stabilized composition which contains: a 5-aminolevulinic acid (5-ALA) compound that is selected from among 5-ALA, a derivative thereof, and a salt of 5-ALA or a derivative thereof; an aqueous medium; and...
|
|
WO/2023/102750A1 |
Provided in the present invention are a fenfluramine hapten, and a preparation method therefor and the use thereof, a fenfluramine artificial antigen, and a fenfluramine antibody. According to the present invention, two haptens, namely h...
|
|
WO/2023/106620A1 |
The present invention relates to a method for producing tyrosine with high purity from a fermented broth containing tyrosine produced by microbial fermentation, the method comprising the steps of: adding a basic solution and dissolving t...
|
|
WO/2023/097691A1 |
Provided is a method for obtaining a high-selectivity β-chiral branched-chain chiral amino acid. The synthetic route of the method for obtaining a high-selectivity β-chiral branched-chain chiral amino acid is: R1 is an alkyl or an aryl...
|
